Effects of a Supervised Exercise Program and a Home Exercise Program in Patients With Systemic Sclerosis
Comparison of the Effects of a Supervised Exercise Program and a Home Exercise Program in Patients With Systemic Sclerosis
1 other identifier
interventional
37
1 country
1
Brief Summary
Scleroderma, also called systemic sclerosis (SSc); It is a heterogeneous multiorgan disease of unknown etiology characterized by vasculopathy, autoimmunity and fibrous tissue. It is stated in studies that cardiac and pulmonary systems are affected in patients with SSc and these effects affect the aerobic capacity, physical functions and quality of life of patients negatively by disrupting their pulmonary and musculoskeletal functions. However, considering the treatment approaches in scleroderma patients, the number of studies evaluating the effectiveness of pulmonary rehabilitation and exercises is limited. Therefore, the purpose of our study; Comparison of the effects of a supervised exercise program and a home exercise program in patients with Systemic Sclerosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jun 2018
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 10, 2018
CompletedFirst Submitted
Initial submission to the registry
November 25, 2020
CompletedFirst Posted
Study publicly available on registry
December 19, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 13, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
April 13, 2021
CompletedApril 14, 2021
February 1, 2021
2.8 years
November 25, 2020
April 13, 2021
Conditions
Outcome Measures
Primary Outcomes (8)
Change in Forced Vital Capacity
Pulmonary function test was applied by Sensor Medics Vmax 22 0,6-2B version spirometer (ERS 1993 Uptake + Zapleta, SensorMedics, Inc, Anaheim, CA, USA). Forced vital capacity (FVC) percent was recorded according to the American Thoracic Society (ATS) / European Respiratory Society (ERS) criteria
Baseline, 12th week
Change in Forced Expiratory Volume in One Second
Pulmonary function test was applied by Sensor Medics Vmax 22 0,6-2B version spirometer (ERS 1993 Uptake + Zapleta, SensorMedics, Inc, Anaheim, CA, USA). Forced expiratory volume in one second (FEV1) percent was recorded according to the American Thoracic Society (ATS) / European Respiratory Society (ERS) criteria
Baseline, 12th week
Change in Forced expiratory volume in one second / Forced vital capacity
Pulmonary function test was applied by Sensor Medics Vmax 22 0,6-2B version spirometer (ERS 1993 Uptake + Zapleta, SensorMedics, Inc, Anaheim, CA, USA). Forced expiratory volume in one second (FEV1)/Forced vital capacity (FVC) ratio percent was recorded according to the American Thoracic Society (ATS) / European Respiratory Society (ERS) criteria
Baseline, 12th week
Change in diffusion capacity
Single breath carbon monoxide method was used in diffusion capacity for carbon monoxide (DLCO) percent measurement
Baseline, 12th week
Change in Maximal Expiratory Pressure
Electronic mouth pressure measuring device was used for respiratory muscle strength. Maximal expiratory pressure (MEP) was measured. MEP was measured from total lung capacity performing a maximal expiratory effort against an occluded airway. MEP measurements was repeated three times, and the maximum percent achieved was recorded
Baseline, 12th week
Change in Maximal Inspiratory Pressure
Electronic mouth pressure measuring device was used for respiratory muscle strength. Maximal inspiratory pressure (MIP) was measured. MIP was measured from residual volume upon a maximal inspiratory effort against an occluded airway. occluded airway. MIP measurements was repeated three times, and the maximum percent achieved was recorded.
Baseline, 12th week
Change in functional capacity
Six-minute walk test (6MWT) is a valid, reliable and useful test for assessing functional capacity of patients. This test assesses distance walked over 6 minutes as a sub maximal test of aerobic capacity/endurance.
Baseline, 12th week
Change in peripheral muscle strength
The Jamar Handgrip Dynamometer is an instrument for measuring the maximum isometric strength of the hand and forearm muscles. Quadriceps isometric muscle strength is measured with a Hand Held Dynamometer.
Baseline, 12th week
Secondary Outcomes (5)
Change in severity of dyspnoea
Baseline, 12th week
Change in fatigue
Baseline, 12th week
Change in quality of life:Health Assessment Questionnaire Disability Index
Baseline, 12th week
Change in quality of life: Scleroderma Health Assessment Questionnaire
Baseline, 12th week
Change in quality of life: Short Form-36 Quality of Life Questionnaire
Baseline, 12th week
Study Arms (2)
Supervised Exercise Group
EXPERIMENTALExercise programs including warm-up, loading, cooling, and relaxation exercises are shown. The warm-up period is consist of light-paced walking, active movements of several large muscle groups. In this loading program; respiratory control training, breathing exercises, posture exercises with respiratory control , walking on the treadmill for 20 minutes without inclination , pedaling in the bicycle ergometer for 10 minutes is taken. Stretching exercises are done during the cooling period. This group was included in an exercise program 2 days a week, 45-90 minutes, for 12 weeks, accompanied by a specialist physiotherapist to the pulmonary rehabilitation unit in the chest diseases ward.
Home Exercise Group
EXPERIMENTALFor patients to do at home (respiratory control training, shrunken lip breathing exhaustion, diaphragmatic, thoracic expansion exercises, posture exercises with respiratory control (pectoral stretching, four-way trunk exercises, head and neck exercises, bilateral shoulder flexion and abduction exercises), sitting and standing exhaustion, and brisk walking to reach 60-85% of the person's maximum heart rate.)), exercises is taught. Patients were asked to do the exercises at home for 45-90 minutes, 2 days a week, for 12 weeks. Participants of the control group are contacted every two weeks via communication methods such as e-mail, message and telephone conversation.Exercise diary is given to all patients and is taken from them at the end of the study.
Interventions
warm-up, loading (respiratory control training, breathing exercises, posture exercises with respiratory control , walking on the treadmill for 20 minutes without inclination , pedaling in the bicycle ergometer for 10 minutes), cooling, and relaxation exercises
Warm-up, loading (respiratory control training, shrunken lip breathing exhaustion, diaphragmatic, thoracic expansion exercises, posture exercises with respiratory control (pectoral stretching, four-way trunk exercises, head and neck exercises, bilateral shoulder flexion and abduction exercises), cooling and relaxation exercises
Eligibility Criteria
You may qualify if:
- Stable clinical status for at least two weeks
- Walking independently
- Volunteer for research study
You may not qualify if:
- Having unstable angina
- Having uncontrolled hypertension
- Having hemodynamic instability
- Participating in any exercise program in the last six months
- Having a major orthopedic or neurological problem that limits functionality
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Dokuz Eylül Üniversitesi School of Physical Therapy and Rehabilitation
Izmir, İzmir, Turkey, 35340, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Hazal Yakut, PT,MSc
Dokuz Eylul University
- STUDY DIRECTOR
Sevgi Özalevli, PT,PhD
Dokuz Eylul University
- STUDY CHAIR
Gerçek Can, MD
Dokuz Eylul University
- STUDY CHAIR
Aylin Özgen Alpaydın, MD
Dokuz Eylul University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal investigator
Study Record Dates
First Submitted
November 25, 2020
First Posted
December 19, 2020
Study Start
June 10, 2018
Primary Completion
April 13, 2021
Study Completion
April 13, 2021
Last Updated
April 14, 2021
Record last verified: 2021-02